Amdipharm links with Invida to develop portfolio in Asia
This article was originally published in Scrip
The UK firm Amdipharm has allied with Invida for the development and commercialisation of a number of its proprietary products in the Asia-Pacific region.
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.